Investor
Relations

We are committed to developing transformational biologic medicines to serve patients with debilitating diseases

Presentations

Date	Title
Jul 01, 2022	AMT Corporate Presentation July 2022
Apr 25, 2022	FILLMORE Chronic Pouchitis Phase 2 Top line Data
Oct 15, 2021	AMT Research & Development Day Presentation